Literature DB >> 12505703

Effects of delta-9-tetrahydrocannabinol on human immune function and host defense.

Michael D Roth1, Gayle C Baldwin, Donald P Tashkin.   

Abstract

This review examines evidence that delta(9)-tetrahydrocannabinol (THC) can regulate and suppress human immune responses. Leukocytes express both cannabinoid receptor type 1 (CB1) and cannabinoid receptor type 2 (CB2), and levels of mRNA encoding for them are increased in peripheral blood leukocytes obtained from marijuana smokers, suggesting cannabinoid receptor activation in vivo. Exposure of human T-cells to THC suppresses their proliferation, inhibits the release of interferon-gamma, and skews the balance of T-helper cytokines towards a type 2 response. The majority of these effects are CB2 receptor-dependent. Consistent with an impact of THC on cell-mediated immunity, alveolar macrophages (AMs) recovered from the lungs of marijuana smokers are suppressed in their ability to release pro-inflammatory cytokines and nitric oxide (NO), and kill bacteria. Macrophage function is restored by treatment with interferon-gamma, a type 1 cytokine. Habitual exposure to THC appears capable of impacting on human cell-mediated immunity and host defense.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12505703     DOI: 10.1016/s0009-3084(02)00159-7

Source DB:  PubMed          Journal:  Chem Phys Lipids        ISSN: 0009-3084            Impact factor:   3.329


  17 in total

1.  Cannabinoid receptor type 1- and 2-mediated increase in cyclic AMP inhibits T cell receptor-triggered signaling.

Authors:  Christine Börner; Michal Smida; Volker Höllt; Burkhart Schraven; Jürgen Kraus
Journal:  J Biol Chem       Date:  2009-12-18       Impact factor: 5.157

Review 2.  Complementary Therapies in Inflammatory Bowel Diseases.

Authors:  Henit Yanai; Nir Salomon; Adi Lahat
Journal:  Curr Gastroenterol Rep       Date:  2016-12

3.  Cannabinoids inhibit T-cells via cannabinoid receptor 2 in an in vitro assay for graft rejection, the mixed lymphocyte reaction.

Authors:  Rebecca Hartzell Robinson; Joseph J Meissler; Jessica M Breslow-Deckman; John Gaughan; Martin W Adler; Toby K Eisenstein
Journal:  J Neuroimmune Pharmacol       Date:  2013-07-04       Impact factor: 4.147

4.  Cannabinoid 2 (CB2) receptor involvement in the down-regulation but not up-regulation of serum IgE levels in immunized mice.

Authors:  Catherine A Newton; Thomas W Klein
Journal:  J Neuroimmune Pharmacol       Date:  2012-05-04       Impact factor: 4.147

5.  Differential effects of self-reported lifetime marijuana use on interleukin-1 alpha and tumor necrosis factor in African American adults.

Authors:  Larry Keen; Arlener D Turner
Journal:  J Behav Med       Date:  2015-03-03

6.  Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor-independent mechanism.

Authors:  Angelo Vaccani; Paola Massi; Arianna Colombo; Tiziana Rubino; Daniela Parolaro
Journal:  Br J Pharmacol       Date:  2005-04       Impact factor: 8.739

7.  Differential migratory properties of monocytes isolated from human subjects naïve and non-naïve to Cannabis.

Authors:  Michelle Sexton; Aurelio Silvestroni; Thomas Möller; Nephi Stella
Journal:  Inflammopharmacology       Date:  2012-04-11       Impact factor: 4.473

Review 8.  Use of cannabinoids as a novel therapeutic modality against autoimmune hepatitis.

Authors:  Rupal Pandey; Venkatesh L Hegde; Narendra P Singh; Lorne Hofseth; Uday Singh; Swapan Ray; Mitzi Nagarkatti; Prakash S Nagarkatti
Journal:  Vitam Horm       Date:  2009       Impact factor: 3.421

Review 9.  Cannabinoid exposure during pregnancy and its impact on immune function.

Authors:  Catherine Dong; Jingwen Chen; Amy Harrington; K Yaragudri Vinod; Muralidhar L Hegde; Venkatesh L Hegde
Journal:  Cell Mol Life Sci       Date:  2018-10-29       Impact factor: 9.261

Review 10.  Interaction between Cannabinoid System and Toll-Like Receptors Controls Inflammation.

Authors:  Kathleen L McCoy
Journal:  Mediators Inflamm       Date:  2016-08-11       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.